Clinical trials: Prostatic Disease
Prostate Cancer
[Al18F]PSMA137 PET/CT Imaging for PSMA-Positive Cancer Patients
To investigate the radioactive uptake of [Al 18 F]PSMA137 in PCa patients, and evaluate the ability of [Al 18 F]PSMA137 to detect PSMA overexpression in PCa patients (especially those with recurrent or advanced PCa).To provide an…
- Trial name
- NCT04693169
- Testing
- 11C-Choline
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking University Cancer Hospital & Institute
Prostate Cancer
A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer
The purpose of this study is to see whether combining 2141-V11 with various standard treatments is an effective treatment approach for prostate cancer. 2141-V11 works by activating the immune system to find and kill cancer cells.
- Trial name
- NCT06347705
- Testing
- 2141-V11 Antibody
- Where
- 7 sites in United States
- Volunteers
- 57 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer
Purpose: Prospective, single-site Phase II study testing whether PSMA-PET/MRI-guided, de-escalated salvage radiation reduces acute Grade ≥2 toxicity versus a 44% historical rate, while maintaining cancer control after…
- Trial name
- NCT07234981
- Testing
- PSMA-guided Salvage Radiation
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- University of Nebraska
Prostate Cancer
Improved Prostate Cancer Diagnosis - Combination of Rapid Prebiopsy Magnetic Resonance Imaging and Biomarkers
This study will enroll 200 men with clinical suspicion of prostate cancer due to higher serum level of PSA than 2.5 ng/ml or abnormal digital rectal examination.
- Trial name
- IMPROD2_0 (NCT02844829)
- Testing
- Prostate MRI
- Where
- Finland
- Volunteers
- 200 people
- Sponsor
- Turku University Hospital
Prostate Cancer
Prostate Cancer Awareness and Initiative for Screening in the European Union
PRAISE-U was initiated on the 1st of April 2023 and is set to last for three years. This collaborative effort involves 25 institutions across 12 countries, all driven by a shared objective: to rationalize prostate cancer…
- Trial name
- PRAISE-U (NCT06424275)
- Testing
- Risk-based screening algorithm
- Where
- 5 sites in Ireland, Lithuania and 2 more
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- European Association of Urology Research Foundation
Prostatic Neoplasms
PSMA-PET and MRI for Detection of Recurrent Prostate Cancer After Radical Treatment
Approximately one third of prostate cancer patients experience biochemical relapse following initial radical prostatectomy or curative radiotherapy.
- Trial name
- NCT04298112
- Testing
- PSMA PET/CT, PSMA PET/MR
- Where
- 3 sites in Norway
- Volunteers
- 300 people
- Sponsor
- Norwegian University of Science and Technology
Transurethral Resection of Prostate, Artery Embolization
Clinical Trial to Evaluate the Efficacy and Safety of the Transarterial Supraselective Embolization of the Prostate to Treat the Urinary Symptoms.
The purpose of this study is to determine whether the transarterial supraselective embolization (TSE) is a technique as effective as transurethral resection of the prostate (TURP) for the treatment of lower urinary tract symptoms…
- Conditions
- Transurethral Resection of Prostate, Artery Embolization, Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
- Trial name
- NCT01963312
- Testing
- Transarterial Supraselective Embolization of the prostate, Transurethral Resection of the prostate
- Where
- Spain
- Volunteers
- 81 people
- Sponsor
- Fundacion Miguel Servet
Metabolic Syndrome, Prostate Cancer
Effect of TyG Index on Outcomes of Radical Prostatectomy
We investigate the association between Triglyserid-Glucose(TyG) index and prostate cancer in patients undergoing radical prostatectomy.
- Conditions
- Metabolic Syndrome, Prostate Cancer, Insulin Resistance
- Trial name
- TyG-PCa (NCT03447028)
- Volunteers
- 200 people
- Sponsor
- Recep Tayyip Erdogan University Training and Research Hospital
Prostate Cancer, Erectile Dysfunction
Can Tadalafil Maintain Erectile Function In Patients Treated With Radiotherapy For Prostate Cancer?
Because of the high incidence of post-radiation erectile dysfunction (ED), up to 72% after external-beam radiotherapy, this patient category represents a most difficult therapeutic challenge.
- Trial name
- NCT00215631
- Testing
- tadalafil
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- Erasmus Medical Center
Prostate Cancer
INTREPId (INTermediate Risk Erection PreservatIon Trial)
This research study is comparing the use of a new form of hormonal therapy used with radiation as a possible treatment for intermediate risk prostate cancer.
- Trial name
- NCT04025372
- Testing
- Bicalutamide, GnRH Agonist, Radiation Therapy
- Where
- 11 sites in United States
- Volunteers
- 234 people
- Sponsor
- Brigham and Women's Hospital
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer
ACCEL is a multicenter, open label phase Ia/Ib/II study of [Ac-225]-PSMA-62 in participants with prostate-specific membrane antigen (PSMA)-positive prostate cancer.
- Conditions
- Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Oligometastatic Prostate Carcinoma, Hormone Sensitive Prostate Cancer
- Trial name
- ACCEL (NCT06229366)
- Testing
- [Ac-225]-PSMA-62 (mCRPC), [Ac-225]-PSMA-62 (OmHSPC)
- Where
- 7 sites in Canada
- Volunteers
- 142 people
- Sponsor
- Eli Lilly and Company
Prostate Cancer
Miami Membrane for Potency (MMEP) Trial
The use of dehydrated human amnionic membrane allograft improves erectile function recovery (as measured by (Sexual History Inventory for Men (SHIM) score) at 12 months after robotic assisted radical prostatectomy (RARP) compared…
- Trial name
- MMEP (NCT02710422)
- Testing
- Amniotic Membrane Placement, EPIC 26, PSA Measurement
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Miami
Prostatic Neoplasms
Continued Treatment With Docetaxel Versus Switch to Cabazitaxel After Minor Prostate Specific Antigen Response to Docetaxel in Patients With Castration-Resistant Metastatic Prostate Cancer
Primary Objective: To compare the continuation of treatment with docetaxel versus switching to cabazitaxel regarding the time to PSA (Prostatic Specific Antigen) progression (TTP-PSA), in patients with Castration-Resistant…
- Trial name
- SWITCH (NCT01576029)
- Testing
- CABAZITAXEL (XRP6258), DOCETAXEL (XRP6976)
- Where
- 8 sites in Brazil
- Volunteers
- 2 people
- Sponsor
- Sanofi
Prostate Cancer
MRI in PROstate Cancer Diagnosis With Prior Risk Assessment
To evaluate the diagnostic performance and cost-effectiveness of the MRI-driven diagnostic pathway of prostate cancer, with upfront individual multivariate risk stratification.
- Trial name
- MR-PROPER (NCT03225222)
- Testing
- biopsy
- Where
- Netherlands
- Volunteers
- 2,558 people
- Sponsor
- Erasmus Medical Center
Prostatic Neoplasms
Endorectal Coil Magnetic Resonance Images (ERC-MRI)
When we acquired MR images of the prostate gland using a coil (receiver antenna) inside the rectum, we can see areas with tumour in the prostate gland, and well as details of the anatomy.
- Trial name
- NCT00160953
- Testing
- Endorectal Coil Magnetic Resonance Images
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto
Prostate Cancer
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
The purpose of this study is to evaluate the efficacy of TAK-385 for achieving and maintaining testosterone suppression.
- Trial name
- NCT02135445
- Testing
- TAK-385, Degarelix
- Where
- 25 sites in United States, United Kingdom
- Volunteers
- 103 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Prostate Cancer
Outpatient Laparoscopic Radical Prostatectomy
The purpose of the study is to evaluate the incidence of surgery-related complications between Day 0 and Day 30.
- Trial name
- LORP (NCT05975775)
- Testing
- Laparoscopic radical prostatectomy
- Where
- France
- Volunteers
- 64 people
- Sponsor
- GCS Ramsay Santé pour l'Enseignement et la Recherche
Prostate Cancer
Use of a Biodegradable Balloon for the Treatment of Prostate Cancer by Intensity Modulated Radiotherapy (BioPro-RCMI)
The benefit of dose escalation in radiotherapy (RT) for biochemical control of prostate cancer is a clearly established fact based on the results of different published prospective trials.
- Trial name
- BioPro-RCMI (NCT02478112)
- Testing
- Biodegradable balloon implant
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Centre Oscar Lambret
Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC)
An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer
This is an open-label Phase II modular study in participants with prostate cancer which will assess safety, efficacy, and tolerability of AZD4635 in combination with other therapeutic agents in different treatment arms (referred…
- Trial name
- NCT04089553
- Testing
- AZD4635, Oleclumab, Durvalumab
- Where
- 9 sites in United States
- Volunteers
- 59 people
- Sponsor
- AstraZeneca
Prostate Cancer, Prostatic Neoplasm
68Ga-HTK03149 for Use as a Diagnostic Radiopharmaceutical
This is a preliminary evaluation of a radiotracer's biodistribution in human subjects. It is a prospective, single-centre, open-label, single group assignment interventional study.
- Conditions
- Prostate Cancer, Prostatic Neoplasm, Prostatic Disease, Urogenital Neoplasms
- Trial name
- NCT04831307
- Testing
- [68Ga]Ga-HTK03149 PET/CT
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- British Columbia Cancer Agency
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.